Assisted Reproductive Technology (ART)

1. Basic Overview

Assisted Reproductive Technology is the core medical solution for infertility, a global reproductive health problem affecting 15% of reproductive-age couples worldwide (WHO data).

Core indications include tubal factor infertility, ovulation disorders (e.g. polycystic ovary syndrome), male factor infertility, recurrent pregnancy loss, unexplained infertility, and infertility caused by endometriosis or advanced reproductive age. ART is divided into core categories: In Vitro Fertilization and Embryo Transfer (IVF-ET), Intracytoplasmic Sperm Injection (ICSI), Preimplantation Genetic Testing (PGT), artificial insemination, and fertility preservation technology (oocyte/ovarian tissue cryopreservation).

2. Standard Treatment Modalities

Conventional IVF-ET & ICSI: The most widely used basic ART, suitable for most infertility cases, with optimized controlled ovarian hyperstimulation protocols to maximize pregnancy rate and reduce complications.
Preimplantation Genetic Testing (PGT): Including PGT-A (aneuploidy screening), PGT-M (monogenic disease testing), PGT-SR (chromosomal structural rearrangement testing), to block genetic diseases and improve implantation success rate, especially for advanced-age couples and recurrent implantation failure patients.
Fertility Preservation: Oocyte cryopreservation, sperm cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation and transplantation, for fertility preservation in patients with malignant tumors, advanced reproductive age, or other medical needs.
Adjuvant Treatment for Difficult Cases: Personalized protocols for recurrent implantation failure, poor ovarian response, and thin endometrium, including intrauterine perfusion, platelet-rich plasma (PRP) therapy, and integrated traditional Chinese and Western medicine treatment.
Artificial Insemination (AI): Including intrauterine insemination (IUI), suitable for mild male factor infertility, unexplained infertility, and ovulation disorders.

3. Core Advantages of Treatment in China

World-leading scale and success rate

China has the largest annual ART cycle volume in the world (over 1 million cycles per year). The clinical pregnancy rate per fresh cycle in top reproductive centers exceeds 50%, on par with top European and American centers; the pregnancy rate for patients under 35 years old exceeds 60%, and the live birth rate for PGT cycles reaches 65%, leading the global average.

Cutting-edge technology with full coverage

China is a global leader in PGT technology, with mature application of PGT for over 400 monogenic genetic diseases, and the largest number of PGT cycles in Asia. It has original optimized protocols for poor ovarian response and advanced-age patients, with a significantly higher pregnancy rate than the global average for patients over 40 years old.

Ultra-high cost performance and short waiting time

The cost of a standard IVF-ET cycle in China is only 3,000–5,000 USD, which is 1/5–1/3 of that in the US (15,000–20,000 USD) and 1/3–1/2 of that in Europe. The waiting time for treatment in top centers is only 1–2 weeks, while it often takes 3–6 months in European and American centers.

Strict regulation and standardized management

China implements strict access management for ART institutions, with standardized operation processes and complete quality control systems, ensuring the safety and compliance of treatment, and avoiding the ethical and legal risks of irregular ART in some countries.

Integrated full-cycle management

Top centers provide a complete service chain from pre-pregnancy examination, ovulation induction, embryo transfer, to pregnancy confirmation and antenatal care, with integrated traditional Chinese and Western medicine adjuvant treatment to significantly improve the live birth rate and reduce the risk of miscarriage.